• About Us
    • About Us
    • Corporate Strategy
    • Our Vision and Values
    • Research & Development
    • Operations
    • Business Development
    • Awards and Grants
  • Announcements
  • Our Team
    • Management Team
    • Scientific Team
    • Scientific Advisory Board
  • Portfolio
    • Our Portfolio
    • Lupuzor™ & Lupus
    • Autoimmunity
    • Anti-infectives
  • Investors
    • Investor Relations
    • AIM Rule 26 Information
    • Regulatory News
    • Market Commentary
    • Share Price
    • Analyst Research
    • Corporate Governance
    • Board of Directors
    • Annual Reports
    • Interviews
    • Professional Advisers
    • Email Alerts
  • Media
    • Events and Conferences
    • Media Room
    • Interviews
    • Scientific Publications
  • Contact Us
Archives
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
February 15, 2016

First US Patients Commence Dosing in Lupuzor’s™ Pivotal Phase III Study

Read More
February 05, 2016

Placing and Subscription Raises £8.3 million

Read More
February 05, 2016

Proposed Placing and Subscription and Notice of General Meeting: 22 February 2016

Read More
December 15, 2015

Over 70 Lupus Specialists Gather in Paris for Lupuzor’s™ Phase III Investigators Meeting

Read More
December 07, 2015

Lupuzor™ Pivotal Phase III Trial Recruiting First US Lupus Patients

Read More
November 04, 2015

Lupuzor™ Phase III Pivotal Trial Update

Read More
October 23, 2015

Board Change

Read More
September 30, 2015

Tim McCarthy Appointed as Non-executive Chairman

Read More
September 30, 2015

Interim Results Announcement for the six months ended 30 June 2015

Read More
July 29, 2015

Richard Warr

Read More
July 27, 2015

ClinicalTrials.Gov registration of LUPUZOR™ Pivotal Phase III Trial

Read More
July 25, 2015

Term Sheet signed with US Investor to secure up to US$14 Million Funding For LUPUZOR™

Read More
  • 1
  • …
  • 12
  • 13
  • 14
  • 15
  • 16
  • …
  • 18
Aim Rule 26 Contact informationDisclaimerPrivacy PolicySite map

© ImmuPharma PLC 2005-2021 | All rights reserved